BrightFocus Foundation is involved in research and funding initiatives aimed at understanding and treating diseases affecting the mind and sight, including Alzheimer's disease, macular degeneration, and glaucoma.

BrightFocus Foundation

Doheny Eye Institute focuses on the conservation, improvement, and restoration of human eyesight, according to self-described mission.

Doheny Eye Institute

Alzheimer's Disease Research

BrightFocus Foundation | 4,533 followers on LinkedIn. Cure in Mind. Cure in Sight.  | BrightFocus Foundation is a nonprofit organization supporting research and providing public education to help eradicate brain and eye diseases, including Alzheimer&#39;s disease, macular degeneration, and glaucoma. We are working to save mind and sight.

BrightFocus is at the forefront of brain and eye health, advancing early-stage, investigator-initiated research around the world.

Seth Perlman

Director, Direct Response Marketing at BrightFocus Foundation

Jennifer Kerchaert

Co-Founder + CEO at Eldera.ai

Dana A. Griffin

Major Gifts Manager at BrightFocus Foundation

Kelly Brown Schoenberger

Could human eyes be given the power to repair themselves? Discover what National Glaucoma Research grant recipient Dr. Jeff Mumm of Wilmer Eye Institute, Johns Hopkins Medicine is learning about the genes involved in the regeneration of retinal ganglion cells—and how the insights could translate to new strategies for restoring vision in people with glaucoma. #Innovation #Research #Health

Linda Van Eldik, director of the UK Sanders-Brown Center on Aging, recently received a three-year, $300,000 award from the BrightFocus Foundation to support her research which hopes to shed light on how specific brain cells may contribute to the progression of Alzheimer’s disease. Learn more: https://lnkd.in/eFFfk-m7

UK Research Communications

Thank you everyone for your supportive comments! And special thank you to BrightFocus Foundation for the trust in my research. I firmly believe that understanding neuronal and glial mechanisms underlying synaptic failure will contribute to the development of targeted therapies for patients with neurodegenerative diseases.

Amira Latif-Hernandez

An international group of dementia experts discovered two new risk factors for dementia—untreated vision loss and high low-density lipoprotein cholesterol. This brings the total number of modifiable risk factors for dementia to 14. Dr. Quincy Samus, a BrightFocus Foundation Alzheimer’s Disease Research grant recipient, breaks it down: https://lnkd.in/ecqyMR2A . #Health #Alzheimers #Dementia

✨ 🔬 Explore the science behind glaucoma, a leading cause of vision loss. Join our Glaucoma Chat today where guest expert Dr. Qi N. Cui of Scheie Eye Institute will discuss the key mechanisms of optic nerve damage, the role of elevated eye pressure, and research into new treatments. #Glaucoma #Podcast #Health

🔍 Unlock the Future of Brain Health at the WHAM Virtual Roundtable! Be part of a transformative conversation on brain health with top experts revealing groundbreaking opportunities to advance women’s brain health—unlocking innovations that can enhance health outcomes for everyone. Alzheimer’s, depression, and other brain health conditions affect women disproportionately, yet critical gaps in funding, awareness, and innovation remain. This roundtable will spotlight these disparities, showcase high-impact solutions, and explore new investment opportunities to drive better outcomes. 💡 Why Attend? • Discover cutting-edge solutions shaping the future of brain health. • Gain insights into diagnostics and treatments for sex-based differences. • Connect with leaders driving brain health innovation. 📅 Tuesday, November 19 | 1:00 - 2:00 PM ET 🔗 Secure your spot now: https://lnkd.in/e83RY7Nk Join us for fresh insights and help shape the future of brain health. Together, we can unlock new possibilities and improve outcomes for all. Meryl Comer , Catherine Bornbaum, PhD, MBA , Emily Goard Jacobs , Sharyn Rossi , BrightFocus Foundation , UC Santa Barbara , UsAgainstAlzheimer's #WomensHealth #WomensHealthInnovation #ADRD #AlzheimersDisease #HealthInnovation #WomensHealthResearch #BrainHealth #Alzheimers #WHAMNow #3Not30

Women's Health Access Matters

Can cannabis-based drugs like synthetic THC & CBD be used to treat Alzheimer's agitation symptoms? Get the latest insights on this topic and other top news from #CTAD24 here: https://lnkd.in/gEdEwrzu . #Science #Cannabis #ResearchNews

Traumatic brain injuries can increase Alzheimer’s risk later in life. Learn what the latest research reveals about protecting your brain health. #BrainInjury #Health #Research

This is a great overview of our positive 52-week data in Mild-to-Moderate #Alzheimers patients at #CTAD2024 by BrightFocus Foundation , supporter of the study. #neurotech #innovation #MedTech #AlzMoonshot #ENDALZ Read it here: https://lnkd.in/em8ad-_8

Sinaptica Therapeutics

Thank you to The Association for Frontotemporal Degeneration (AFTD) and Dr. Brad Dickerson of Massachusetts General Hospital for speaking on our recent Zoom In on Dementia & Alzheimer’s episode to discuss frontotemporal dementia (FTD). In case you missed it, we covered… ✔️ The genetics behind FTD ✔️ Emerging treatment options ✔️ Clinical trials and how to get involved Watch the episode on-demand. ⤵️

Metric
Company Name	BrightFocus Foundation	Doheny Eye Institute
Symbol
MSH ID	ORG:BRIGHTFOCUS	ORG:DOHENY
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Nonprofit/Charity	Medical Research
Country	US	US
Stage
Employee Count
Website	brightfocus.org	doheny.org
LinkedIn	brightfocus-foundation	doheny-eye-institute
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		3.63K
Web Traffic Growth		0.22
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BRIG

ORG:BRIGHTFOCUS

BrightFocus Foundation

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue